The Burrill Personalized Medicine Meeting
Featured SpeakersGeorge Poste
Regents’ Professor and holds the Del E. Webb Chair of Health Innovation
Arizona State University
George Poste is a Regents’ Professor and holds the Del E. Webb Chair of Health Innovation at Arizona State University (ASU). He founded and built The Biodesign Institute at ASU and served as its Director from 2003 to 2009. In 2009 he launched the Complex Adaptive Systems Initiative (CASI) at ASU. This new program integrates research across multiple schools at ASU by using genetic engineering and high performance computing to study the altered regulation of molecular networks in human diseases for the purpose of developing new diagnostic tests for personalized medicine and the remote monitoring of health status using miniaturized body sensors and mobile devices.
He has published more than 350 research papers and edited 14 books on pharmaceutical technologies, cancer and infectious diseases. He has received honorary degrees in science, law and medicine for his research contributions and was honored in 1999 by Her Majesty, Queen Elizabeth II as a Commander of the British Empire for his contributions to international healthcare and security.
He serves on the Board of Directors of Monsanto, Exelixis, Caris Life Sciences, and the Scientific Advisory Boards of Burrill and Company and Synthetic Genomics. From 1992 to 1999, he was Chief Science and Technology Officer and President, R&D, of SmithKline Beecham (SB). During his tenure at SB, he was associated with the successful registration of 31 drug, vaccine and diagnostic products. In 2004, he was named Scientist of the Year by R&D Magazine; in 2006, he received the Einstein Award from the Global Business Leadership Council; and in 2009, he received the Scrip Lifetime Achievement Award voted by the leadership of the global pharmaceutical industry.
He is a Fellow of the U.K. Royal Society, the Royal College of Pathologists and the U.K. Academy of Medicine, a Distinguished Fellow at the Hoover Institution, Stanford University, a member of the Council for Foreign Relations and the U. S. Institute of Medicine Board on Global Health. He has served as a member of the Defense Science Board of the U.S. Department of Defense and currently serves on advisory committees for several U.S. government agencies in defense, intelligence, national security and healthcare.
Professor of Genetics
Harvard Medical School
George Church is Professor of Genetics, Harvard Medical School, Director of PersonalGenomes.org, providing the world's only open-access information source for human Genomic, Environmental & Trait data (GET). His 1984 Harvard PhD included the first methods for direct genome sequencing, molecular multiplexing, barcoding & automation. These lead to the first commercial genome sequence (pathogen, Helicobacter pylori) in 1994 . His innovations in "next generation" genome sequencing and synthesis & cell/tissue engineering resulted in 12 companies including medical genomics ( Knome, Alacris, AbVitro, GoodStart, Pathogenica ), synthetic biology ( LS9, Joule , Gen9, Warp Drive ) as well as new privacy, biosafety & biosecurity policies. He is director of the NIH Center for Excellence in Genomic Science. His honors include election to NAS & NAE, Hoogendijk Prize & Franklin Laureate for Achievement in Science.
Chief Business Officer
Dr. Dombkowski is Chief Business Officer at 23andMe. She was previously a member of the company’s Board of Directors and was a Managing Director at MPM Capital. Prior to this, she was a Healthcare Equity Analyst for Tiger Management and for Dresdner RCM Global Investors. Dr. Dombkowski holds a Ph.D. in Mathematics from Rice University and a B.A. in Mathematics from Wellesley College.
President & Chief Executive Officer
Jay was appointed President and CEO of Illumina in 1999, and has taken the company from $1.3 million in sales in 2000 to over $1 billion in 2011, representing a compound annual growth rate in excess of 90%. He oversaw the company’s expansion into the whole genome sequencing area with the acquisition of Solexa in 2006, and more recently into diagnostics and consumer sequencing. Under his leadership, Illumina has been named multiple times to the Deloitte & Touche Fast 50 and Fast 500 lists, as well as to the Forbes 25 Fastest-Growing Tech Companies (2007, 2009 and 2010,) and the Fortune 100 Fastest-Growing Companies (2010) lists.
Previously, Jay served as President and Chief Executive Officer of Molecular Dynamics, later acquired by Amersham Pharmacia Biotech and now a part of GE Healthcare. As a co-founder and member of the board of directors for Molecular Dynamics he led the company to its initial public offering in 1993. While there, he also helped Molecular Dynamics develop and launch over 15 major instrumentation systems, including the first capillary-based DNA sequencer.
Prior to joining Molecular Dynamics, Jay was Vice President of engineering and strategic planning for Plexus Computers, a manufacturer of high-performance Unix super-microcomputers. Before his career at Plexus, Jay was Executive Vice President for Manning Technologies and held various manufacturing positions while working for the Autolab division of Spectra Physics. Currently, he is a trustee of the Keck Graduate Institute of Applied Life Sciences and a member of the Board of Directors at Illumina, Inc and at Coherent, Inc.
Jay received a B.A. in economics from Claremont McKenna College and a B.S. and M.S. (summa cum laude) in industrial engineering from Stanford University.
Personalized Medicine Coalition
Edward Abrahams, Ph.D., is president of the Personalized Medicine Coalition (PMC). Representing scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products for the benefit of patients and the health system. It has grown from its original 18 founding members in 2004 to over 200 today.
Previously Dr. Abrahams was Executive Director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University.
Dr. Abrahams worked for seven years for the U.S. Congress, including as a legislative assistant to Senator Lloyd Bentsen, an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for the House Committee on the Interior.
The author of numerous essays, Dr. Abrahams serves as senior editor of Personalized Medicine and has also taught history and public policy at Brown University and the University of Pennsylvania.
President and CEO
David Levison is the Founder, Chief Executive Officer, and Director of CardioDx. Prior to launching CardioDx, David was a Venture Partner at Texas Pacific Group Ventures and was the interim Chief Executive Officer of XDx, Inc., a molecular diagnostic company focused on the immune system. Previously, he was the founder, President and Chief Executive Officer of iScribe, a healthcare technology company acquired by AdvancePCS (now Caremark) in December 2001. Prior to iScribe, David was President of Oncology Therapeutics Network (OTN), which was acquired by Bristol-Myers Squibb in 1996. David also served as Chief Financial Officer of OTN's parent company, Axion, from 1990 to 1993. Prior to Axion, he was with Cole Gilburne Fund, an early stage, technology-focused venture capital firm. David received his M.B.A. from Stanford University and B.S. from Williams College.
Andrew Fish is Executive Director of AdvaMedDx, an advocacy organization representing leading manufacturers of medical diagnostic tests. AdvaMedDx operates as a division of AdvaMed, the medical device manufacturers association, where Mr. Fish holds the title of Senior Executive Vice President. Mr. Fish has extensive government relations, legal, regulatory, and policy background in food, drug, health, and agriculture issues. Prior to joining AdvaMedDx in 2010, Mr. Fish was Senior Vice President of Legal and Government Affairs, General Counsel, and Secretary for the Consumer Healthcare Products Association (CHPA), representing manufacturers of non-prescription medicines.
Mr. Fish also worked for the American Cancer Society as Senior Director of Federal Government Relations. Earlier in his career, he served in the Senate-confirmed post of Assistant Secretary of Agriculture for Congressional and Intergovernmental Affairs, after twice working for the U.S. Senate Agriculture Committee, first as a professional staff member and later as deputy chief counsel. Mr. Fish’s work in private practice focused on biotech regulation, as well as on a wide range of food, drug and agriculture issues.
Mr. Fish is a graduate of Yale University and Stanford Law School.